FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766994906> ?p ?o ?g. }

• W2766994906 endingPage "A399" @default.
• W2766994906 startingPage "A399" @default.
• W2766994906 abstract "MIDO is under EMA review for treatment of newly diagnosed adult patients with FLT3 mutation-positive AML who are eligible to receive stem cell transplantation (SCT). The objective of this study was to estimate the Incremental Cost Effectiveness Ratio (ICER) of utilizing MIDO+SOC followed by MIDO monotherapy, compared to SOC for newly diagnosed AML in the UK. A partition survival model was developed to estimate the expected outcomes and costs of treatment with MIDO+SOC vs SOC over a lifetime horizon. The model included the following health states/partitions: induction, consolidation, monotherapy, complete remission (CR), relapse, SCT treatment, SCT recovery, and post-SCT recovery. Data on CR, overall survival (OS), and frequencies of adverse events (AEs) were obtained from the MIDO Phase III clinical trial (RATIFY). OS was extrapolated beyond the trial horizon using a “cure model” approach and data from the Office for National Statistics (2013-2015). Published health state utilities were used. Routine care utilisation was based on the data used in the NICE STA for azacitidine TA399. Costs incorporated in the model included drugs and administration, AE treatment, and medical costs for hospitalisations, physician visits, and end-of-life/palliative care. Unit costs were obtained from various sources including the Personal Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care (2015). Incremental life years (LYs) and quality adjusted life years (QALYs) gained by patients on MIDO+SOC vs. SOC were 1.67 and 1.47 respectively. At an incremental cost for £50,404 over a lifetime horizon, the ICER per LY was £30,263 and £34,327 per QALY. Sensitivity analysis results were also consistent with the basecase findings With a threshold of £50,000 per QALY for end-of-life treatment, MIDO is a cost-effective option for newly-diagnosed FLT3 mutation-positive AML. With limited treatments in FLT3 mutation-positive AML, MIDO represents a new cost-effective option." @default.
• W2766994906 created "2017-11-10" @default.
• W2766994906 creator A5037902575 @default.
• W2766994906 creator A5048804624 @default.
• W2766994906 creator A5061613530 @default.
• W2766994906 creator A5074164996 @default.
• W2766994906 creator A5075394669 @default.
• W2766994906 date "2017-10-01" @default.
• W2766994906 modified "2023-10-14" @default.
• W2766994906 title "Cost-Effectiveness Analysis of Midostaurin (MIDO) with Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)" @default.
• W2766994906 doi "https://doi.org/10.1016/j.jval.2017.08.005" @default.
• W2766994906 hasPublicationYear "2017" @default.
• W2766994906 type Work @default.
• W2766994906 sameAs 2766994906 @default.
• W2766994906 citedByCount "0" @default.
• W2766994906 crossrefType "journal-article" @default.
• W2766994906 hasAuthorship W2766994906A5037902575 @default.
• W2766994906 hasAuthorship W2766994906A5048804624 @default.
• W2766994906 hasAuthorship W2766994906A5061613530 @default.
• W2766994906 hasAuthorship W2766994906A5074164996 @default.
• W2766994906 hasAuthorship W2766994906A5075394669 @default.
• W2766994906 hasBestOaLocation W27669949061 @default.
• W2766994906 hasConcept C112930515 @default.
• W2766994906 hasConcept C126322002 @default.
• W2766994906 hasConcept C2779900020 @default.
• W2766994906 hasConcept C3019080777 @default.
• W2766994906 hasConcept C64332521 @default.
• W2766994906 hasConcept C71924100 @default.
• W2766994906 hasConceptScore W2766994906C112930515 @default.
• W2766994906 hasConceptScore W2766994906C126322002 @default.
• W2766994906 hasConceptScore W2766994906C2779900020 @default.
• W2766994906 hasConceptScore W2766994906C3019080777 @default.
• W2766994906 hasConceptScore W2766994906C64332521 @default.
• W2766994906 hasConceptScore W2766994906C71924100 @default.
• W2766994906 hasIssue "9" @default.
• W2766994906 hasLocation W27669949061 @default.
• W2766994906 hasOpenAccess W2766994906 @default.
• W2766994906 hasPrimaryLocation W27669949061 @default.
• W2766994906 hasRelatedWork W1991263975 @default.
• W2766994906 hasRelatedWork W2005049219 @default.
• W2766994906 hasRelatedWork W2066175645 @default.
• W2766994906 hasRelatedWork W2159627298 @default.
• W2766994906 hasRelatedWork W2472742574 @default.
• W2766994906 hasRelatedWork W2999841909 @default.
• W2766994906 hasRelatedWork W3048642956 @default.
• W2766994906 hasRelatedWork W3125858761 @default.
• W2766994906 hasRelatedWork W3160419021 @default.
• W2766994906 hasRelatedWork W4237494110 @default.
• W2766994906 hasVolume "20" @default.
• W2766994906 isParatext "false" @default.
• W2766994906 isRetracted "false" @default.
• W2766994906 magId "2766994906" @default.
• W2766994906 workType "article" @default.